MDXG

MKT CAP:$515M

MiMedx Group, Inc.

Market Cap

$515M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$3.31-$3.17 (-48.84%)

Apr 23, 2026

Company Details

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the...

CEO

Joseph H. Capper

IPO Date

Feb 12, 2008

Website

www.mimedx.com

Key Metrics TTM

Revenue

$393M

+32.9% YoY

Net Income

$41M

EPS (Diluted)

$0.27

Free Cash Flow

$64M

Revenue / Share

$2.63

Gross Margin

82.0%

Operating Margin

13.7%

Net Margin

10.4%

FCF Margin

16.1%

P/S

1.3x

P/E

12.6x

Earnings Reports

Q4 2025

Apr 29, 2026

PENDING

FY 2025

Feb 25, 2026

$419MEPS $0.32

Q3 2025

Oct 29, 2025

$114MEPS $0.11

Q2 2025

Jul 30, 2025

$99M+13.1%EPS $0.06

Q1 2025

Apr 30, 2025

$88MEPS $0.05

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 20	$54M	$45M	-$6M
Q3 20	$64M	$54M	-$10M
Q4 20	$69M	$58M	-$16M
Q1 21	$60M	$50M	-$7M
Q2 21	$68M	$55M	-$410.0K
Q3 21	$63M	$53M	-$1M
Q4 21	$67M	$57M	$3M
Q1 22	$59M	$49M	-$9M
Q2 22	$67M	$55M	-$10M
Q3 22	$68M	$56M	-$7M
Q4 22	$74M	$60M	$1M
Q2 24	$87M	$72M	$23M
Q4 24	$93M	$76M	$11M
Q1 25	$88M	$72M	$8M
Q2 25	$99M	$80M	$12M
Q3 25	$114M	$95M	$22M

Valuation

Quarter	P/S	P/E
Q2 20	2.0x	—
Q3 20	2.8x	—
Q4 20	3.7x	—
Q1 21	4.1x	—
Q2 21	5.2x	—
Q3 21	2.7x	—
Q4 21	2.7x	—
Q1 22	2.0x	—
Q2 22	1.6x	—
Q3 22	1.3x	—
Q4 22	1.4x	—
Q2 24	3.3x	—
Q4 24	4.3x	85.9x
Q1 25	3.3x	35.3x
Q2 25	2.5x	21.6x
Q3 25	2.6x	25.1x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 20	-$3M	-$4M
Q3 20	-$5M	-$5M
Q4 20	-$10M	-$12M
Q1 21	-$7M	-$9M
Q2 21	$2M	$1M
Q3 21	$6M	$6M
Q4 21	-$3M	-$4M
Q1 22	-$10M	-$10M
Q2 22	-$3M	-$3M
Q3 22	$959.0K	$610.0K
Q4 22	-$6M	-$7M
Q2 24	$22M	$21M
Q4 24	$19M	$19M
Q1 25	$5M	$5M
Q2 25	$14M	$14M
Q3 25	$29M	$25M

Capital Expenditures

Quarter	CapEx
Q2 20	$410.0K
Q3 20	$652.0K
Q4 20	$2M
Q1 21	$2M
Q2 21	$452.0K
Q3 21	$610.0K
Q4 21	$325.0K
Q1 22	$172.0K
Q2 22	$380.0K
Q3 22	$349.0K
Q4 22	$2M
Q2 24	$419.0K
Q4 24	$0
Q1 25	$377.0K
Q2 25	$0
Q3 25	$4M

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 20	-20.4%	-29.6%
Q3 20	-27.6%	-0.9%
Q4 20	-10.3%	+4.1%
Q1 21	-2.9%	-11.5%
Q2 21	+27.1%	+15.2%
Q3 21	-1.9%	-13.3%
Q4 21	-1.7%	-24.3%
Q1 22	-1.8%	+2.1%
Q2 22	-1.9%	+11.6%
Q3 22	+7.3%	+16.6%
Q4 22	+10.3%	+14.4%
Q2 24	+48.1%	-6.5%
Q4 24	+38.9%	+7.0%
Q1 25	+30.3%	+6.9%
Q2 25	+32.6%	+17.6%
Q3 25	+30.4%	+43.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 20	$4M	8.3%
Q3 20	$4M	5.7%
Q4 20	$0	0.0%
Q1 21	$3M	5.4%
Q2 21	$4M	6.0%
Q3 21	$4M	6.0%
Q4 21	$4M	5.4%
Q1 22	$4M	6.8%
Q2 22	$4M	6.6%
Q3 22	$0	0.0%
Q4 22	$2M	2.5%
Q2 24	$4M	4.7%
Q4 24	$0	0.0%
Q1 25	$4M	4.8%
Q2 25	$5M	4.8%
Q3 25	$5M	4.3%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q2 20	$2M	—	—	$49M
Q3 20	$3M	—	—	$60M
Q4 20	$3M	—	—	$69M
Q1 21	$4M	—	—	$53M
Q2 21	$4M	—	—	$52M
Q3 21	$4M	—	—	$49M
Q4 21	$5M	—	—	$49M
Q1 22	$6M	—	—	$52M
Q2 22	$6M	—	—	$59M
Q3 22	$6M	—	—	$56M
Q4 22	$5M	—	—	$50M
Q2 24	$3M	—	—	$46M
Q4 24	$4M	—	—	$61M
Q1 25	$3M	—	—	$60M
Q2 25	$3M	$16M	$48M	—
Q3 25	$4M	—	—	$69M

Revenue Segments

Quarter	Advanced Wound Care, Tissue And Other	Advanced Wound Care, Umbilical Cord-Derived	Product and Service, Other
Q4 22	$68M	$6M	$29.0K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$76M	$0	$76M
Q2 22	$73M	$0	$73M
Q3 22	$73M	$0	$73M
Q4 22	$66M	$0	$66M
Q1 23	$61M	$0	$61M
Q2 23	$69M	$0	$69M
Q3 23	$81M	$0	$81M
Q4 23	$82M	$0	$82M
Q1 24	$48M	$0	$48M
Q2 24	$69M	$0	$69M
Q3 24	$89M	$0	$89M
Q4 24	$104M	$0	$104M
Q1 25	$106M	$0	$106M
Q2 25	$119M	$0	$119M
Q3 25	$142M	$0	$142M
Q4 25	$166M	$0	$166M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 20	108M	+0.5%	+1.1%
Q3 20	108M	+0.3%	-1.0%
Q4 20	109M	+0.3%	+1.2%
Q1 21	109M	+0.5%	+1.7%
Q2 21	110M	+0.8%	+2.0%
Q3 21	111M	+0.4%	+2.0%
Q4 21	113M	+2.2%	+4.0%
Q1 22	112M	-1.4%	+2.0%
Q2 22	113M	+1.1%	+2.3%
Q3 22	113M	+0.5%	+2.5%
Q4 22	114M	+0.2%	+0.4%
Q2 24	149M	+31.0%	+33.4%
Q4 24	149M	+0.1%	+32.1%
Q1 25	150M	+0.4%	+31.9%
Q2 25	149M	-0.2%	+31.4%
Q3 25	150M	+0.3%	+0.5%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 20	$77.1K	696
Q3 20	$92.4K	696
Q4 20	$93.3K	735
Q1 21	$81.6K	735
Q2 21	$92.7K	735
Q3 21	$85.8K	735
Q4 21	$83.1K	811
Q1 22	$72.6K	811
Q2 22	$82.5K	811
Q3 22	$83.5K	811
Q4 22	$85.8K	867
Q2 24	$97.4K	895
Q4 24	$111.0K	837
Q1 25	$105.4K	837
Q2 25	$117.8K	837
Q3 25	$135.9K	837

Revenue / Employee